Cargando…
Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)
INTRODUCTION: Accurate PD-L1 testing for non-small cell lung cancer (NSCLC) maximizes the benefits of immune checkpoint inhibitor (ICI) drugs like pembrolizumab. False negative test results deny ICI treatments to eligible patients, worsening clinical and economic outcomes, while false positives incr...
Autores principales: | Hurwitz, Jason T., Vaffis, Shannon, Grizzle, Amy J., Nielsen, Søren, Dodson, Andrew, Parry, Suzanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681966/ https://www.ncbi.nlm.nih.gov/pubmed/35556235 http://dx.doi.org/10.1007/s40487-022-00197-1 |
Ejemplares similares
-
In vitro diagnostic medical device regulation (IVDR): the end of laboratory developed tests (LDT)?
por: Barberis, Massimo
Publicado: (2021) -
Harmonization of Clinical Laboratory Test Results: The Role of the IVD Industry
por: Armbruster, Dave, et al.
Publicado: (2016) -
Diagnosis of Parkinson’s Disease by A Metabolomics-Based Laboratory-Developed Test (LDT)
por: Lokhov, Petr G., et al.
Publicado: (2020) -
Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson’s Disease
por: Lokhov, Petr G., et al.
Publicado: (2020) -
Epigenetic IVD Tests for Personalized Precision Medicine in Cancer
por: Beltrán-García, Jesús, et al.
Publicado: (2019)